Cel Sci (CVM) Operating Expenses (2010 - 2026)
Cel Sci (CVM) posted Operating Expenses of $5.3 million for Q1 2026, down 0.8% sequentially from $5.4 million in Q4 2025, and down 16.7% YoY from $6.4 million in Q1 2025.
Cel Sci (CVM) Operating Expenses (2010 - 2026) Analysis & Trends
Cel Sci has reported Operating Expenses for 17 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Operating Expenses fell 16.7% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 14.81% YoY) and the FY2025 annual result came in at $24.8 million, down 5.85% from the prior year.
- Operating Expenses eased to $5.3 million in Q1 2026 per CVM's latest filing, from $5.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $9.6 million in Q1 2022 and troughed at $5.3 million in Q1 2026.
- A 5-year average of $7.1 million and a median of $6.9 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses increased 11.94% in 2022, then decreased 22.12% in 2025.
- Over 5 years, Operating Expenses stood at $7.7 million in 2022, then decreased by 15.22% to $6.5 million in 2023, then increased by 6.28% to $6.9 million in 2024, then declined by 22.12% to $5.4 million in 2025, then decreased by 0.8% to $5.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.3 million, $5.4 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 541.02 Mn |
| 10 | Cel Sci | 2.21 Mn | -4.33 Mn | - | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.33 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 6.03 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 6.39 Mn |
| Dec 31, 2024 | 6.89 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 6.67 Mn |
| Mar 31, 2024 | 7.08 Mn |
| Dec 31, 2023 | 6.49 Mn |
| Sep 30, 2023 | 7.47 Mn |
| Jun 30, 2023 | 8.18 Mn |
| Mar 31, 2023 | 8.18 Mn |
| Dec 31, 2022 | 7.65 Mn |
| Sep 30, 2022 | 8.95 Mn |
| Jun 30, 2022 | 8.72 Mn |
| Mar 31, 2022 | 9.55 Mn |
| Dec 31, 2021 | 8.84 Mn |
| Sep 30, 2021 | 8.47 Mn |
| Jun 30, 2021 | 10.46 Mn |